NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company stated that its proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy. The outbreak has continued to expand, with 1,561 confirmed cases and 506 deaths in the DRC as of July 6. No approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains. The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study.
The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. NanoViricides is focused on advancing NV-387 into Phase II human clinical trials.
For more information, visit https://ibn.fm/LaNwF.
